Published on: Mon, Jan 13 2014
The Epilepsy Foundation, a non-profit organization working to ensure that people with seizures have the opportunity to live their lives to their fullest potential, announced a partnership today with Poliwogg, an innovative financial firm transforming healthcare investing, that will encourage investment and support for new therapies to help people living with recurrent seizures.
“Encouraging innovation is a central pillar of our mission,” said Philip M. Gattone, president and CEO of the Epilepsy Foundation. “We are celebrating this partnership during the first anniversary of our merger with the Epilepsy Therapy Project. The partnership with Poliwogg leverages the strength of the merged organization’s combined resources to make an even bigger difference in the lives of all people living with seizures.”
“Poliwogg can help promising new therapies that have received early funding support and high marks from our Scientific and Business Advisory Boards make the leap into clinical development,” said Warren Lammert, chair of the Epilepsy Foundation. “The Foundation can supply an audience of investors who are motivated to bring better therapies to people with epilepsy.”
According to Lammert, “Poliwogg can help us reach a broader set of investors looking for innovative products and companies. I am thrilled about our partnership with Poliwogg and the opportunity to leverage the work and investment we are making to accelerate new therapies.”
“Foundations have an enormously important role to play in identifying companies with promising approaches to improving the quality of life for people affected by debilitating and deadly diseases,” said Greg Simon, CEO of Poliwogg. “The Epilepsy Foundation is a leader in bringing scientific and business diligence to bear in the interest of people with epilepsy. Poliwogg is proud to work with the Epilepsy Foundation as part of our mission to help fund promising companies by making health investments more accessible to millions of people.”
When a person has two or more unprovoked seizures, they have epilepsy, which affects more than 2 million people in the United States and 65 million people worldwide. This year, another 150,000 people in our country will be diagnosed with epilepsy. Despite all available treatments, 4 out of 10 people with epilepsy continue to experience uncontrolled seizures while many more experience less than optimal seizure control.
About the Epilepsy Foundation
The Epilepsy Foundation, a national non-profit with 47 affiliated organizations throughout the United States, has led the fight against seizures since 1968. The Foundation is an unwavering ally for individuals and families impacted by epilepsy and seizures. The Foundation works to prevent, control and cure epilepsy through community services; public education; federal and local advocacy; and supporting research into new treatments and therapies. The Foundation works to ensure that people with seizures have the opportunity to live their lives to their fullest potential. For additional information, please visit http://www.epilepsy.com.
The Epilepsy Foundation is the largest non-governmental funder of epilepsy research, with a 45-year history of encouraging innovation in the field. Most of the top epilepsy scientists and researchers working in America today received funding from the Foundation – especially, early in their careers.
"Like" the Epilepsy Foundation on Facebook at http://www.facebook.com/epilepsyfoundationofamerica and follow us on Twitter at http://www.twitter.com/epilepsyfdn.
Poliwogg is an innovative financial firm transforming healthcare investing. We provide pathways for accredited investors to invest in early stage companies in health and life sciences, structure indexes that quantify the impact of public companies in health, and are launching sector specific publicly registered venture funds focused by health vertical. Our mission is to transform health from a cost to an asset class. For more information, visithttp://www.poliwogg.com. Follow Poliwogg on Twitter @poliwoggpond, and on LinkedIn.